LivaNova adds Donald Zurbay to its board

LivaNova PLC reported that its Board of Directors appointed Donald Zurbay as a director and member of the Audit and Compliance Committee, effective September 4, 2025.

Rhea-AI Filing Summary

LivaNova PLC reported that its Board of Directors appointed Donald Zurbay as a director and member of the Audit and Compliance Committee, effective September 4, 2025. He brings more than 20 years of leadership experience in healthcare, including serving as President, Chief Executive Officer and director of Patterson Companies, Inc. from October 2022 to May 2025, and previously as its Chief Financial Officer from June 2018 to October 2022. He also held senior finance roles at St. Jude Medical, Inc., including Chief Financial Officer.

As a non-executive director, Zurbay will be compensated under LivaNova’s Remuneration Policy, including an annual board retainer of $70,000, an Audit and Compliance Committee member fee of $15,000, and an annual service-based restricted stock award valued at $185,000, all prorated until the 2026 Annual General Meeting. The company states there is no special arrangement leading to his selection and no related-party transactions requiring disclosure.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did LivaNova (LIVN) announce in this 8-K?

LivaNova PLC announced that its Board appointed Donald Zurbay as a director and as a member of the Audit and Compliance Committee, with his term beginning on September 4, 2025.

What is Donald Zurbay’s professional background relevant to LivaNova (LIVN)?

Donald Zurbay has over 20 years of healthcare leadership experience. He was President, CEO and a director of Patterson Companies, Inc. from October 2022 to May 2025, and its Chief Financial Officer from June 2018 to October 2022. Before that, he spent 13 years at St. Jude Medical, Inc. in senior finance roles, including Vice President and Corporate Controller and later Chief Financial Officer.

How will LivaNova (LIVN) compensate new director Donald Zurbay?

Under LivaNova’s Remuneration Policy, Donald Zurbay will receive an annual board retainer of $70,000, an Audit and Compliance Committee annual member fee of $15,000, and an annual service-based restricted stock award with a fair market value of $185,000, each prorated for his service until the 2026 Annual General Meeting.

Are there any related-party transactions between LivaNova (LIVN) and Donald Zurbay?

The company states that there is no arrangement or understanding with any person under which Donald Zurbay was selected as a director. It also notes that he is not, and has not been since January 1, 2024, a participant in any transaction with LivaNova, nor in any proposed transaction, that would require disclosure under Item 404(a) of Regulation S-K.

What board committee will Donald Zurbay serve on at LivaNova (LIVN)?

Donald Zurbay will serve as a member of LivaNova’s Audit and Compliance Committee in addition to his role on the Board of Directors.

When does Donald Zurbay’s initial service period at LivaNova (LIVN) run through?

The compensation for Donald Zurbay’s role as a non-executive director, including cash fees and restricted stock awards, is stated to be prorated for his service until the 2026 Annual General Meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 09:07 AM Learn about SEC filing dates

LIVANOVA PLC0001639691false00016396912025-09-032025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

LivaNova PLC

(Exact Name of Registrant as Specified in its Charter)

England and Wales

001-37599

98-1268150

(State or Other Jurisdiction  of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

20 Eastbourne Terrace

London, W2 6LG

United Kingdom

(Address of Principal Executive Offices)

+44 20 33250660

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name on each exchange on which registered
Ordinary Shares - £1.00 par value per share			LIVN			NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director

On September 3, 2025, the Board of Directors (the “Board”) of LivaNova PLC (the “Company”) appointed Donald Zurbay to the Board and as a member of the Audit and Compliance Committee of the Board. His term begins September 4, 2025.

Mr. Zurbay has served in numerous key leadership positions at different healthcare companies over the past 20 years. Most recently, Mr. Zurbay was the President, Chief Executive Officer and a member of the board of directors of Patterson Companies, Inc. (“Patterson Companies”), a distributor of dental and animal health products and services, from October 2022 until May 2025. Prior to that time, Mr. Zurbay served as the Chief Financial Officer of Patterson Companies from June 2018 to October 2022. Prior to working at Patterson Companies, Mr. Zurbay spent 13 years with St. Jude Medical, Inc., formerly a global medical device company, where he served in various leadership roles including Vice President and Corporate Controller from March 2004 to August 2012, and Chief Financial Officer from August 2012 to February 2017.

Consistent with the Company’s other non-executive directors, Mr. Zurbay will be compensated in accordance with the Company’s Remuneration Policy (the “Policy”). In connection with this appointment and pursuant to the Policy, Mr. Zurbay will receive an annual board retainer fee of $70,000, an Audit and Compliance Committee annual member fee of $15,000, and an annual, service-based restricted stock award grant with a fair market value of $185,000, in each case prorated for his service until the 2026 Annual General Meeting.

There is no arrangement or understanding between Mr. Zurbay and any other person pursuant to which Mr. Zurbay was selected as a director. In addition, Mr. Zurbay is not, and has not been since January 1, 2024, a participant in any transaction involving the Company, and Mr. Zurbay is not a participant in any proposed transaction with the Company, in each case, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits

(d)    Exhibits.

Exhibit						Description
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			LivaNova PLC
Date: September 4, 2025			By: /s/ Michael Hutchinson
			Name: Michael Hutchinson
			Title: SVP, Company Secretary & Chief Legal Officer